Teras Lauren R, DeSantis Carol E, Cerhan James R, Morton Lindsay M, Jemal Ahmedin, Flowers Christopher R
Strategic Director, Hematologic Cancer Research, Epidemiology Research Program, American Cancer Society, Atlanta, GA.
Director, Breast and Gynecological Cancer Surveillance, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.
CA Cancer J Clin. 2016 Nov 12;66(6):443-459. doi: 10.3322/caac.21357. Epub 2016 Sep 12.
Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36%-56%, depending on race/sex), while those with mycosis fungoides had among the best survival (79%-92%). For B-cell lymphomas, 5-year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology. CA Cancer J Clin 2016;66:443-459. © 2016 American Cancer Society.
总体而言，淋巴瘤是美国第四大常见癌症，也是癌症死亡的第六大主要原因。作者根据2008年世界卫生组织分类提供了按亚型划分的当代淋巴瘤统计数据，包括美国最新的发病率和生存数据。首次呈现了按亚型划分的美国淋巴瘤病例总数估计以及发病率和生存统计的详细评估。2016年，预计有136,960例新发淋巴瘤。近年来淋巴瘤总体发病率有所下降，但各亚型趋势不同。前体淋巴细胞肿瘤发病率从2001年到2012年有所上升，尤其是B细胞肿瘤。在成熟淋巴细胞肿瘤中，浆细胞肿瘤增长最快。套细胞淋巴瘤（男性）、边缘区淋巴瘤、毛细胞白血病和蕈样肉芽肿的发病率也有所上升。与发病率一样，成熟T细胞淋巴瘤和成熟B细胞淋巴瘤的生存率因亚型和种族而异。外周T细胞淋巴瘤患者的5年相对生存率最差（36%-56%，取决于种族/性别），而蕈样肉芽肿患者的生存率最佳（79%-92%）。对于B细胞淋巴瘤，边缘区淋巴瘤患者的5年生存率为83%至91%；毛细胞白血病患者为78%至92%；但伯基特淋巴瘤患者的生存率低至47%至63%，浆细胞肿瘤患者为44%至48%。总体而言，黑人男性在所有淋巴瘤亚型中的生存率最低。这些当代发病率和生存统计数据有助于制定这些癌症的管理策略，并可为其病因提供线索。《CA：临床医师癌症杂志》2016年；66：443-459。©2016美国癌症协会。
